HC Wainwright Comments on Senseonics FY2025 Earnings

Senseonics Holdings, Inc. (NYSE:SENS - Free Report) - Stock analysts at HC Wainwright issued their FY2025 earnings estimates for Senseonics in a report issued on Monday, June 2nd. HC Wainwright analyst S. Lee anticipates that the company will earn ($0.07) per share for the year. HC Wainwright currently has a "Buy" rating and a $1.10 price objective on the stock. The consensus estimate for Senseonics' current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Senseonics' Q4 2025 earnings at ($0.01) EPS, Q1 2026 earnings at ($0.01) EPS, Q2 2026 earnings at ($0.01) EPS and FY2027 earnings at ($0.03) EPS.

Senseonics (NYSE:SENS - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.09). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. During the same period in the previous year, the business posted ($0.07) earnings per share.

Several other equities analysts have also recently weighed in on SENS. Wall Street Zen raised shares of Senseonics to a "sell" rating in a research note on Monday, May 12th. Mizuho began coverage on Senseonics in a research report on Thursday, April 10th. They set an "outperform" rating and a $2.00 price objective for the company.

Senseonics Price Performance

SENS traded down $0.01 during trading on Wednesday, reaching $0.53. 5,752,659 shares of the company traded hands, compared to its average volume of 6,761,183. Senseonics has a 12-month low of $0.25 and a 12-month high of $1.40. The firm has a fifty day simple moving average of $0.61 and a 200 day simple moving average of $0.65. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The company has a market cap of $345.62 million, a P/E ratio of -4.06 and a beta of 0.97.

Institutional Trading of Senseonics

A number of large investors have recently made changes to their positions in the business. First Light Asset Management LLC bought a new position in shares of Senseonics in the 4th quarter valued at about $3,366,000. Geode Capital Management LLC lifted its stake in shares of Senseonics by 9.7% in the 4th quarter. Geode Capital Management LLC now owns 6,405,100 shares of the company's stock valued at $3,354,000 after purchasing an additional 566,704 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Senseonics by 6,694.1% in the 4th quarter. Jane Street Group LLC now owns 6,118,786 shares of the company's stock worth $3,203,000 after purchasing an additional 6,028,726 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Senseonics by 4.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,502,326 shares of the company's stock worth $2,298,000 after purchasing an additional 162,628 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Senseonics during the 4th quarter valued at approximately $720,000. 12.36% of the stock is currently owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.